Novo Nordisk A/S (NVO) — Stock Price, Chart & Analysis
Novo Nordisk A/S (NVO) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $174.02B and a trailing P/E ratio of 9.87. Over the past 52 weeks, NVO has traded between $35.12 and $64.16. Novo Nordisk A/S pays a dividend yielding 4.6%. View the live NVO chart, technical opinion, analyst ratings, fundamentals and latest news below.
Novo Nordisk A/S (NVO) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $174.02B |
| P/E ratio (TTM) | 9.87 |
| EPS (TTM) | $3.99 |
| Dividend yield | 4.6% |
| 52-week high | $64.16 |
| 52-week low | $35.12 |
| Beta | 0.34 |
| Avg. volume | 12.15M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Novo Nordisk A/S (NVO)
How much does one share of Novo Nordisk A/S cost?
As of the latest update, one share of Novo Nordisk A/S (NVO) trades at $100 (+0.00% today).
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S has a market capitalization of approximately $174.02B.
What is Novo Nordisk A/S's P/E ratio?
Novo Nordisk A/S has a trailing price-to-earnings (P/E) ratio of 9.87.
What is Novo Nordisk A/S's earnings per share (EPS)?
Novo Nordisk A/S's trailing twelve-month EPS is $3.99.
Does Novo Nordisk A/S pay a dividend?
Yes — Novo Nordisk A/S pays a dividend with a yield of 4.6% ($1.80 per share annually).
What is Novo Nordisk A/S's 52-week trading range?
Over the past year, NVO has traded between $35.12 and $64.16.
What is the analyst price target for Novo Nordisk A/S?
The mean analyst price target for Novo Nordisk A/S is $46.47. This is informational only and not investment advice.
Latest Novo Nordisk A/S (NVO) news
- Novo Nordisk CEO Says Company Open to Direct NYSE Share ListingNews · Sep 23, 2026
- Novo Nordisk Gets Regulatory Nod in Singapore for Wegovy Treatment of Certain Liver AilmentsNews · Sep 23, 2026
- Novo Nordisk Just Made a Surprising Move Beyond Weight LossNews · Sep 22, 2026
- Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old ProblemsNews · Sep 22, 2026
- Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.News · Sep 22, 2026
- AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’News · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live NVO dashboard…